Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 2Phase 2 2Phase 1/2 2Phase 4 1Phase 1 1

Status

Completed 3Recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Multiple Myeloma 168Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Recurrence 28Leukemia 24Vomiting 23Neoplasms, Plasma Cell 20Lymphoma 18Neoplasms 16Nausea 13Burkitt Lymphoma 11Prostatic Neoplasms 8Immunoglobulin Light-chain Amyloidosis 7Carcinoma, Non-Small-Cell Lung 6Lymphoma, Follicular 5Lung Neoplasms 5Hodgkin Disease 5Ovarian Neoplasms 4Neoplasm Metastasis 4Lymphoma, Non-Hodgkin 4Leukemia, Biphenotypic, Acute 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Paraproteinemias 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Fallopian Tube Neoplasms 3

Interventions

Paclitaxel 79Carboplatin 64Bevacizumab 33liposomal doxorubicin 29Topotecan 28Gemcitabine 25Cisplatin 19olaparib 18Drug Therapy 12Doxorubicin 12Taxes 11niraparib 9Docetaxel 6CP protocol 6Trabectedin 5Hyperthermic Intraperitoneal Chemotherapy 5Etoposide 5Cyclophosphamide 51-dodecylpyridoxal 5rucaparib 4pembrolizumab 4avelumab 4atezolizumab 4Immunoglobulin G 4Ifosfamide 4Disulfides 4Dexamethasone 4Chemotherapy, Adjuvant 4trebananib 3fluzoparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Ovarian Neoplasms × Dexamethasone × Clear all
NCT06824467 2026-05-08

TroFuse-022

Merck Sharp & Dohme LLC

Phase 3 Recruiting
770 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06007586 2025-12-04

Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients

Sichuan Cancer Hospital and Research Institute

Phase 3 Completed
143 enrolled
Gynecologic

Uterine Cervical Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms, Vomiting, Endometrial Neoplasms

NCT01846611 2019-04-01

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Janssen Research & Development, LLC

Phase 3 Completed
581 enrolled 14 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT00113607 2014-06-27

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3 Completed
672 enrolled 14 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡